EirTree issued a press release announcing the pre-launch of a new product, its spray-on CBD isolate formula called Hypo CBD. The product is still patent pending and features CBD isolates that are combined with the platform’s clinically proven HypoSpray Delivery Platform. The product is manufactured in a GMP-standard facility.
The press release explains that a challenge with today’s CBD products is identifying just how much CBD one is getting into their body. The brand’s latest product, EirTree, can help users receive the transparency that they need to determine just how much CBD they are getting. Further, the GMP manufacturing and pharma industry standard can ensure that the impurities and other Cannabis compounds are minimized and that there is just CBD isolate to support the body.
Long H. Vu, the founder and CEO of Eir Tree stated in the press release,
“We are excited to introduce HYPO CBD to the market. After receiving the feedback from earl adopters and seeing their amazing results, we are reminded again of the potential of HYPO CBD. Through advanced science, EirTree strives to provide products that make a difference today.”
The brand’s overall mission is to provide its customers with access to advanced science through products that work to help support and balance their lifestyle. The platform collaborates with scientific leaders in the field of health and transdermal delivery. For more info check https://www.eirtreehealth.com/
All information is for general informational and educational purposes only. Nothing should be interpreted as legal or wellness advice.